Why the study?
Does amiodarone accelerate ventricular rate in patients with atrial fibrillation and Wolff-Parkinson-White syndrome?
Does amiodarone accelerate ventricular rate in patients with atrial fibrillation and Wolff-Parkinson-White syndrome?
Amiodarone can paradoxically accelerate ventricular rate in patients with atrial fibrillation and Wolff-Parkinson-White syndrome, highlighting the need for careful electrophysiological assessment prior to use.
Answers are grounded in this paper and cite their sources.
Potential risk with amiodarone in AF-WPW; hypothesis-generating case leaves open need for confirmatory data.
Amiodarone has proved to be a valuable drug in atrial fibrillation associated with the Wolff-Parkinson-White syndrome. When it was administered to a patient with this syndrome in atrial fibrillation, who had previously suffered an inferior myocardial infarction, the ventricular rate accelerated from 170 to 230 beats/minute.This unusual case emphasises the need for full electrophysiological assessment of patients with the Wolff-Parkinson-White syndrome for whom amiodarone treatment is being considered.
No takes yet. Share an insight, caveat, or question.
Sheinman et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: